 |
市場調査レポート
商品コード
371116
フランスのコンシューマーヘルス市場Consumer Health in France |
||||||
| フランスのコンシューマーヘルス市場 |
|
出版日: 2020年10月28日
発行: Euromonitor International
ページ情報: 英文 123 Pages
納期: 即納可能
 |
当レポートでは、フランスのコンシューマーヘルス (OTC医薬品) 市場について包括的に調査分析し、最新の小売販売データ、主要企業プロファイル、主要ブランドについて検証するほか、市場に影響を与える戦略的分析、市場予測などについて、体系的な情報を提供しています。
※以下カテゴリーは、分冊での販売も承っております。価格や内容については、お問い合わせください。
The outbreak of COVID-19 is expected to lead to an increase in growth and sales for consumer health products in 2020, with 4% value growth predicted, compared to 1% recorded in 2019. Much of this growth will be driven by panic buying, with some French consumers stockpiling goods during Q1 and Q2 of 2020 when the lockdown was in place, with consumers ensuring they had essential goods in the home. Many consumers were also concerned about contracting the virus, and therefore, they wanted to have me...
Euromonitor International's‘Consumer Health in France report’ offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2015-2019, allowing you to identify the sectors driving growth. Forecasts to 2024 illustrate how the market is set to change.
Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management and Wellbeing.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
List OF CONTENTS AND TABLES
EXECUTIVE SUMMARY
COVID-19 impact on consumer health
COVID-19 country impact
Company response
Retailing shift
What next for consumer health?
MARKET INDICATORS
MARKET DATA
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
GLOBAL MACROECONOMIC ENVIRONMENT
GLOBAL INDUSTRY ENVIRONMENT
DISCLAIMER
DEFINITIONS
SOURCES
KEY DATA FINDINGS
2020 IMPACT
Acetaminophen benefits from the outbreak of COVID-19 as the Minster of Health recommends its use to fight off a fever
Nonsteroidal analgesics and anti-inflammatory medications move from over-the-counter, to behind-the-counter status
Sanofi benefits from the increasing interest in paracetamol as leading product Doliprane improves its share
RECOVERY AND OPPORTUNITIES
Better performance across the forecast period, as acetaminophen continues to improve its growth
Codeine restrictions put a damper on growth for the forecast period, with anti-inflammatories and aspirin also becoming increasingly unpopular
Growth is challenged as several medications move from OTC to BTH, impacting brand awareness and value sales
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Supervision of the distribution of vasoconstrictors and distrust of anti-cough medicines leads to a decline in value growth for 2020
Antihistamines/allergy remedies (systemic) drive growth as the early Spring has consumers reaching for solutions to hay fever and pollen-related allergies
Solinest continues to grow through the positive performance of Ricola, while Reckitt Benckiser is set to lose share
RECOVERY AND OPPORTUNITIES
Growth continues to record a decline over the forecast period, as antihistamines/allergy remedies (systemic) remain the key driver of growth
A move to behind-the-counter impacts growth over the forecast period, while Strepfen lozenges become prescription only
The growing mistrust of cold products increases consumers interest in natural alternatives across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Lifestyle changes due to home seclusion lead to an increase in sales of digestive remedies during Q1 and Q2 of 2020
Value growth aligns to 2019; however, motion sickness remedies see a decline in demand during Q1 and Q2, as the COVID-19 lockdown stifles sales
Johnson & Johnson leads the landscape with Imodium, as Sanofi offers the most popular product, Maalox
RECOVERY AND OPPORTUNITIES
Higher growth across the forecast period, as antacids continue to drive sales for digestive remedies
Findings published in 2020 are set to impact growth for certain diarrhoeal remedies over the forecast period
Natural remedies set to challenge growth across the forecasts period, as COVID-19 increases the interest in health and wellbeing
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
COVID-19 increases skin conditions caused by stress, however, lockdown and social distancing reduces demand for antiparasitics/lice (head and body) treatments
Negative press surrounding side-effects of Propecia stifle growth; however, hair loss treatments remain on an upward trend
Johnson & Johnson Sante Beaute France retains its lead, while Bayer Sante Familiale offers leading product Bepanthen
RECOVERY AND OPPORTUNITIES
Growth will increase year-on-year across the forecast period, as hair loss treatment and antiparasitics/lice (head and body) treatments recover in 2021
Lice treatment centres are set to stifle growth for antiparasitics/lice (head and body) treatments, across the forecast period
The increasing popularity of natural products, as well as a shift towards dietary changes, may stifle growth across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Growth is stifled as the government implements limitations on nicotine substitutes, during the initial outbreak of COVID-19
The national tobacco control plan and the National Authority for Health both recommend the use of NRT smoking cessation aids, boosting growth in the landscape
Pierre Fabre Health Care and Johnson & Johnson Laboratories lead the landscape, making it tough for competitors to gain share
RECOVERY AND OPPORTUNITIES
The COVID-19 virus motivates some consumers to purchase nicotine substitutes, however, growth continues to decline across the forecast period
The reimbursement of NRT smoking cessation aids will negatively impact growth for OTC goods across the forecast period
Competition from e-vapour products contributes to the decline in volume and value growth across the forecast period
CATEGORY INDICATORS
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
An increase in stress and anxiety due to the outbreak of COVID-19 boosts growth for sleep aids in 2020
A quarter of French people suffer from a lack of sleep, a statistic that boosts value growth for sleep aids
Players benefit from the outbreak of COVID-19, with most players recording double-digit growth during 2020
RECOVERY AND OPPORTUNITIES
Positive results predicted across the forecast period, with double-digit value growth until 2025
Growth for sleeping aids is set to benefit from consumers increased concerns around prescription sleeping pills
Growth is challenged by the number of alternative options, impacting sales of sleeping aids
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Growth is set to be positive, as the hay fever season begins earlier in 2020, boosting sales for eye care products
COVID-19 drives the use of eyedrops, as the lockdown increases use of screen time for both work and in-home entertainment
Laboratoires Chauvin retains its lead, as all players record positive growth as consumers continue to invest in products during the outbreak of COVID-19
RECOVERY AND OPPORTUNITIES
Ongoing growth will be supported by digital devices and screen use, which may continue to rise following habits established during the outbreak of COVID-19
Half of the local population could suffer from allergies within the next 20 years, with rising levels boosting growth for eye care across the forecast period
Standard eye care benefits from increasing cases of dry eye disease, with the ageing population boosting growth
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
COVID-19 leads to a decline in value growth, as lockdown reduces physical activity and injuries
A lack of innovation stifles growth; however, sticking plasters/adhesive bandages lead the landscape, with a wide variety of goods
Laboratoires URGO continues to grow its share in 2020, while Laboratories Mercurochrome benefits from offering a wide range of products
RECOVERY AND OPPORTUNITIES
Growth will be supported by the return to outdoor activities, with consumers taking part in their normal routines following the COVID-19 restrictions
The ageing population supports ongoing growth across the forecast period, with older consumers more likely to need wound care items
Despite positive values sales, demographic trends are set to stifle growth across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
COVID-19 leads to a considerable uplift in growth, as consumers stockpile vitamins that benefit the immune system
Multivitamins record double-digit growth, despite being challenged by the national press that recommends relying on food sources instead
The high demand for vitamins boosts sales for major players, as Berocca increases its market share
RECOVERY AND OPPORTUNITIES
Growth will decline following the uplift aligned to the COVID-19 outbreak; however, sales will continue to benefit from consumers maintaining the habit of taking vitamins
Multivitamins will continue out selling single vitamins across the forecast period
Innovations focused on vitamin C, and immunity-boosting ingredients is predicted for the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
COVID-19 increases sales, as consumers reach for dietary supplements to aid their immune system and boost their energy levels
Probiotics, and those supplements that aid relaxation and calm stress, have seen an increase in growth due to the impact of COVID-19
Merck Medication Familiale SAS boosts sales of Bion due to the outbreak of COVID-19, whereas Arkogelules from Laboratoires Arkopharma SA loses share
RECOVERY AND OPPORTUNITIES
Growth across the forecast period will remain positive, driven by combination herbal/traditional dietary supplements
Probiotic supplements continue to drive positive growth, as gut health becomes increasingly important
A lack of regulations leads to consumers questioning effectiveness, challenging growth across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Weight gain acquired during the COVID-19 lockdown period, boosts sales of weight loss supplements
A decline in value growth reflects the growing attitude that a healthier diet and exercise are the key to weight management, above quick-fix solutions
Nutrition & Sante maintains its lead, as Feed continues to gain a solid reputation
RECOVERY AND OPPORTUNITIES
Value growth is set to improve across the forecast period, with all areas recording positive growth by 2022
Slimming tea will lead both volume and value growth across the forecast period
Weight loss supplements offered by sports or nutrition players provide an opportunity for growth across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Value sales are stifled by the closure of gyms across the country; however, growth remains positive as consumers use sports nutrition to maintain muscle
As non-essential retailers close, an increase in share will be seen from supermarkets and hypermarkets, as well as e-commerce
Myprotein remains the leading brand, increasing its share on the highly competitive landscape
RECOVERY AND OPPORTUNITIES
Growth will recover following the outbreak of COVID-19, as consumers return to their previous fitness regimes
Growth opportunities include the growing vegan and flexitarian lifestyles, as well as high protein diets and rising on-the-go-consumption of protein/energy bars
The growth of e-commerce and an increase in online players is set to drive sales across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
The outbreak of COVID-19 boosts the consumption of products that help relieve stress and aid relaxation
Herbal/traditional sleep aids records the strongest value growth, as heightened anxieties increase sleep deprivation
Laboratoires Arkopharma leads the landscape in 2020, benefiting from the popularity of both Arkogelules and Arkofluides
RECOVERY AND OPPORTUNITIES
Growth is set to return to pre-COVID-19 levels from 2021, remaining positive across the forecast period
Herbal/traditional products face growing competition from aromatherapy, set to stifle growth across the forecast period
A shift from OTC to herbal/traditional products, aligned to the growing health trend, aids strong growth across the forecast period
CATEGORY DATA
KEY DATA FINDINGS
2020 IMPACT
Paediatric vitamins and dietary supplements, nappy (diaper) rash treatments and paediatric acetaminophen all benefit from the outbreak of the COVID-19 virus
Cough/cold remedies are set to record the sharpest decline in growth as mistrust for the products grows
Bayer Sante Familiale SAS leads the landscape, with Merck Medication Familiale SAS also benefiting from the current climate
RECOVERY AND OPPORTUNITIES
Following an uplift in sales due to COVID-19, sales are set to decline from 2021; however, growth will remain steady and positive across the forecast period
The landscape will be increasingly challenged by natural alternatives, as OTC options continue to cause concern
Innovation remains limited; however, opportunities exist for paediatric vitamins and dietary supplements
CATEGORY DATA
比較リスト
